How will precision medicine handle privacy concerns moving forward?
The U.S. Food and Drug Administration switched perspectives concerning patient-centric medicine on Feb. 19 when it approved the marketing of genetics testing company 23andMe’s carrier test for Bloom Syndrome – bringing it back to life after previous ethical/technical issues. Generally speaking, this was great news and demonstrates the FDA’s willingness to adapt, but there are still […]